Reshape the Fates of Treg and CD8+T Cells Through IL‐2Rα by Synergizing Divergent Receptor‐Biased IL‐2 PEGylates

Abstract Clinical trials of receptor‐biased interleukin‐2 (IL‐2) variants in cancer therapy show limited efficacy. To investigate, we re‐evaluated divergent receptor‐biased IL‐2 PEGylates (generated via site‐specific PEGylation at residues D20 (not‐β) and Y45 (not‐α)), alone or in combination. Resul...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jiaqi Sun, Lingfeng Guo, Dezhong Ji, Mengfan Yu, Boyang Cheng, Xingxing Zhu, Yeshuang Yuan, Siyu Wu, Yuanjie Zhang, Wen Shi, Zhiqian Chen, Xindang Chu, Jiayu Hu, Liwen Hua, Yiming Wang, Yanning Zhu, Yu Mu, Hanwen Sun, Chuanling Zhang, Qi Wang, Sulong Xiao, Lihe Zhang, Bo Zhang, Demin Zhou
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-05-01
Serie:	Advanced Science
Soggetti:	CD8+ T interleukin‐2 PEGylation tumor immunotharapy
Accesso online:	https://doi.org/10.1002/advs.202414931
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!